Genetic Biomarker Prevalence Is Similar in Fecal Immunochemical Test Positive and Negative Colorectal Cancer Tissue
Authors:
- Theodore R. LevinTLTheodore R. Levin
- Douglas A. CorleyDCDouglas A. Corley
- Christopher D. JensenCJChristopher D. Jensen
- Amy R. MarksAMAmy R. Marks
- Wei K. ZhaoWZWei K. Zhao
- Alexis M. ZebrowskiAZAlexis M. Zebrowski
- Virginia P. QuinnVQVirginia P. Quinn
- Lawrence W. BrowneLBLawrence W. Browne
- William R. TaylorWTWilliam R. Taylor
- David A. AhlquistDADavid A. Ahlquist
- Graham P. LidgardGLGraham P. Lidgard
- Barry M. BergerBBBarry M. Berger
- 2 January 2017
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 62 (3) , 678-688
Abstract
Background Fecal immunochemical test (FIT) screening detects most asymptomatic colorectal cancers. Combining FIT screening with stool-based genetic biomarkers increases sensitivity for cancer, but whether DNA biomarkers (biomarkers) differ for cancers detected versus missed by FIT screening has not been evaluated in a community-based population. Aims To evaluate tissue biomarkers among Kaiser Permanente Northern California patients diagnosed with colorectal cancer within 2 years after FIT screening. Methods FIT-negative and FIT-positive colorectal cancer patients 50–77 years of age were matched on age, sex, and cancer stage. Adequate DNA was isolated from paraffin-embedded specimens in 210 FIT-negative and 211 FIT-positive patients. Quantitative allele-specific real-time target and signal amplification assays were performed for 7 K-ras mutations and 10 aberrantly methylated DNA biomarkers (NDRG4, BMP3, SFMBT2_895, SFMBT2_896, SFMBT2_897, CHST2_7890, PDGFD, VAV3, DTX1, CHST2_7889). Results One or more biomarkers were found in 414 of 421 CRCs (98.3%). Biomarker expression was not associated with FIT status, with the exception of higher SFMBT2_897 expression in FIT-negative (194 of 210; 92.4%) than in FIT-positive cancers (180 of 211; 85.3%; p = 0.02). There were no consistent differences in biomarker expression by FIT status within age, sex, stage, and cancer location subgroups. Conclusions The biomarkers of a currently in-use multi-target stool DNA test (K-ras, NDRG4, and BMP3) and eight newly characterized methylated biomarkers were commonly expressed in tumor tissue specimens, independent of FIT result. Additional study using stool-based testing with these new biomarkers will allow assessment of sensitivity, specificity, and clinical utility.Keywords
Funding Information
- National Cancer Institute (U54CA163262)
This publication has 16 references indexed in Scilit:
- Clinical Performance of an Automated Stool DNA Assay for Detection of Colorectal NeoplasiaClinical Gastroenterology and Hepatology, 2013
- Next-Generation Stool DNA Test Accurately Detects Colorectal Cancer and Large AdenomasGastroenterology, 2012
- Stool DNA screening for colorectal neoplasia: biological and technical basis for high detection ratesPathology, 2012
- Toward standardizing and reporting colorectal cancer screening indicators on an international level: The international colorectal cancer screening networkInternational Journal of Cancer, 2011
- Organized Colorectal Cancer Screening in Integrated Health Care SystemsEpidemiologic Reviews, 2011
- A novel hypothesis on the sensitivity of the fecal occult blood testCancer, 2009
- Evaluating Test Strategies for Colorectal Cancer Screening: A Decision Analysis for the U.S. Preventive Services Task ForceAnnals of Internal Medicine, 2008
- Screening for Colorectal Neoplasms With New Fecal Occult Blood Tests: Update on Performance CharacteristicsJNCI: Journal of the National Cancer Institute, 2007
- CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancerNature Genetics, 2006
- BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectumGut, 2004